--- schema_version: "secwatch.filing_event.v1" accession: "0001564590-23-004187" form_type: "8-K" ticker: "VTAK" cik: "0001716621" company_name: "Catheter Precision, Inc." filed_at: "2023-03-22T23:59:59+00:00" generated_at: "2026-06-17T21:27:17.065694+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.5 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Ra Medical stockholders approve issuance of >19.99% of common stock on warrants and units ## Summary - Proposal 1 approved: issuance of >19.99% of common stock upon exercise of Series E warrants; 259,937 for, 77,670 against. - Proposal 2 approved: issuance of >19.99% of common stock on Class A/B units and Series F/G warrants; 262,554 for. - Proposal 3 approved: issuance of common stock on conversion of Series X preferred (Catheter Precision merger); 268,043 for. - Proposal 4 ratified: Haskell & White LLP as auditor for FY2022; 1,248,217 for, 29,547 against. - All proposals passed; broker non-votes of 960,122 on proposals 1-3. ## SEC filing metadata - accession: 0001564590-23-004187 - form_type: 8-K - ticker: VTAK - cik: 0001716621 - company_name: Catheter Precision, Inc. - filed_at: 2023-03-22T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.5 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/rmed-8k_20230321.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001564590-23-004187 - JSON: https://secwatch.observer/filing/0001564590-23-004187.json - Plain text: https://secwatch.observer/filing/0001564590-23-004187.txt ## Key facts - Shareholder Votes Catheter Precision, Inc. shareholders approved Approval of issuance of common stock upon conversion of Series X Preferred Stock at the 2023-03-21 meeting. - Outcome: passed - Meeting: 2023-03-21 source text: 3. Proposal No. 3: Approval, in Accordance with NYSE American Company Guide Section 712(b), the Issuance of Shares of Company Common Stock upon Conversion of Outstanding Series X Preferred Stock. In accordance with NYSE American Company Guide Section 712(b), the issuance of the Common Stock upon conversion of the Company’s Series X Convertible Preferred Stock, par value $0.0001 per share, which shares of Series X Convertible Preferred Stock were issued upon the closing of the merger between the Company and Catheter Precision, Inc., was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 268,043 70,714 6,088 960,122 evidence_url: https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm - Shareholder Votes Catheter Precision, Inc. shareholders approved Approval of issuance of more than 19.99% of outstanding common stock upon exercise of Series E warrants at the 2023-03-21 meeting. - Outcome: passed - Meeting: 2023-03-21 source text: 1. Proposal No. 1: Approval of, in Accordance with NYSE American Company Guide Section 713(a), the Issuance of More than 19.99% of the Company’s Outstanding Common Stock. In accordance with NYSE American Company Guide Section 713(a), the issuance of more than 19.99% of our outstanding common stock, par value $0.0001 per share upon the exercise of our Series E Common Stock Purchase Warrants, with the right for such potential exercise to occur immediately, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 259,937 77,670 7,238 960,122 evidence_url: https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm - Shareholder Votes Catheter Precision, Inc. shareholders approved Approval of adjournment of Special Meeting at the 2023-03-21 meeting. - Outcome: passed - Meeting: 2023-03-21 source text: 5. Proposal No. 5: Approval of the Adjournment of the Special Meeting. The approval of the adjournment of the Special Meeting, if necessary, to continue to solicit votes for Proposal Nos. 1, 2, 3 and 4 was approved based on the following results of voting, although no such adjournment was required as a result of Proposal Nos. 1, 2, 3 and 4 being approved: Votes For Votes Against Abstentions Broker Non-Votes 1,181,196 87,075 36,696 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm - Shareholder Votes Catheter Precision, Inc. shareholders approved Ratification of independent registered public accounting firm Haskell & White LLP at the 2023-03-21 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-03-21 source text: 4. Proposal No. 4: Ratification of Auditors. The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 1,248,217 29,547 27,203 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm - Shareholder Votes Catheter Precision, Inc. shareholders approved Approval of issuance of more than 19.99% of common stock in connection with sale of Class A and B units and upon exercise of Series F and G warrants and conversion of Series A Preferred at the 2023-03-21 meeting. - Outcome: passed - Meeting: 2023-03-21 source text: 2. Proposal No. 2: Approval of, in Accordance with NYSE American Company Guide Section 713(a), the Issuance of More than 19.99% of the Company’s Outstanding Common Stock. In accordance with NYSE American Company Guide Section 713(a), the issuance of more than 19.99% of our outstanding Common Stock (a) in connection with our sale of Class A units, which contain shares of common stock and Series F and G Common Stock Purchase Warrants, and Class B units, which contain shares of Series A Convertible Preferred Stock and Series F and G Common Stock Purchase Warrants, and (b) upon the exercise of the Series F and G Common Stock Purchase Warrants and the conversion of Series A Convertible Preferred Stock, with the right for such potential exercise or conversion to occur immediately, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 262,554 75,678 6,613 960,122 evidence_url: https://www.sec.gov/Archives/edgar/data/1716621/000156459023004187/0001564590-23-004187-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.